HIGHLIGHTS
- who: Orly Vardeny from the Europe and Saudi Arabia have published the paper: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial, in the Journal: (JOURNAL) of 21/Oct/2022
- what: The aim of this analysis was to determine the efficacy and safety of dapagliflozin in patients with HFimpEF.
SUMMARY
The Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial demonstrated that the SGLT2 inhibitor dapagliflozin reduced the risk of cardiovascular death, HF hospitalization or urgent HF visits . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.